Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study a,b,c
James F. Trotter(Baylor Scott & White Health), James E. Everhart(Memorial Health University Medical Center), Brenda W. Gillespie(University of Michigan–Ann Arbor), Kim M. Olthoff(University of Pennsylvania), Robert M. Merion(University of Kansas Medical Center), Michaël Abécassis(University of Arizona), Robert S. Brown(Cornell University), Robert A. Fisher(University of Connecticut), Carl L. Berg(Duke University), Paul H. Hayashi(United States Food and Drug Administration), Norah A. Terrault(University of Southern California)
Cited by 64
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
The International Position on Laparoscopic Liver Surgery
|Annals of Surgery|2009|1.5k
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors
|Liver Transplantation|2010|1.2k